Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What's New And What's Next In CAR-T After ASH

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment

Related Content

Celgene's CAR-T Leadership Goals Advance At ASH 2017

Dec 12 2017

A Cellectis Trial Death Points To Challenges Ahead For CAR-T

Sep 05 2017

CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients

Nov 03 2017

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Oct 19 2017

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Related Companies

Novartis AG

Gilead Sciences, Inc.

Kite Pharma, Inc.

Genetix Biotherapeutics

Bristol Myers Squibb Company

Amgen, Inc.

AstraZeneca PLC

Cellectis SA

Pfizer Inc.

Les Laboratoires Servier

Additional Topics

ImmunoOncology Market Access Reimbursement Commercial Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window